MBX
MBX Biosciences, Inc. Common Stock
Biotechnology
Market Cap$1.55B
5Y Perf.+33.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MBX vs CYCN
Revenue, margins, valuation, and 5-year total return — side by side.
CYCN
Cyclerion Therapeutics, Inc.
Biotechnology
Market Cap$14M
5Y Perf.+21.6%
MBX vs CYCN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MBX | CYCN |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.55B | $14M |
| Revenue (TTM) | $0.00 | $2M |
| Net Income (TTM) | $-80M | $-4M |
| Gross Margin | — | 100.0% |
| Operating Margin | — | -239.8% |
| Total Debt | $171K | $0.00 |
| Cash & Equiv. | $49M | $3M |
MBX vs CYCN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MBX
CYCN
| Stock | Sep 24 | May 26 | Return |
|---|---|---|---|
| MBX Biosciences, In… (MBX) | 100 | 133.6 | +33.6% |
| Cyclerion Therapeut… (CYCN) | 100 | 121.6 | +21.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MBX vs CYCN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MBX leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. Cyclerion Therapeutics, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
MBX
MBX Biosciences, Inc. Common Stock
The Long-Run Compounder
MBX carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 46.8% 10Y total return vs CYCN's -98.7%
- 2.3% margin vs CYCN's -170.1%
- +220.5% vs CYCN's -8.2%
Best for: long-term compounding
CYCN
Cyclerion Therapeutics, Inc.
The Income Pick
CYCN is the clearest fit if your priority is income & stability and growth exposure.
- beta 0.94
- Rev growth 3.7%, EPS growth 9.9%, 3Y rev CAGR 91.1%
- Lower volatility, beta 0.94, current ratio 5.15x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CYCN | 3.7% revenue growth vs MBX's -46.0% |
| Quality / Margins | MBX | 2.3% margin vs CYCN's -170.1% |
| Stability / Safety | CYCN | Beta 0.94 vs MBX's 1.33 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | MBX | +220.5% vs CYCN's -8.2% |
| Efficiency (ROA) | MBX | -20.1% ROA vs CYCN's -35.6%, ROIC -96.9% vs -65.1% |
MBX vs CYCN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
MBX vs CYCN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMBXLAGGINGCYCN
CYCNCyclerion Therapeutic…
0leads
MBXMBX Biosciences, Inc.…
3leads
6 Total Categories
CATEGORYLEADERvs CYCNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MBX1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MBX5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
MBX5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
MBX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
CYCN and MBX operate at a comparable scale, with $2M and $0 in trailing revenue.
| Metric | MBXMBX Biosciences, … | CYCNCyclerion Therape… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $2M |
| EBITDAEarnings before interest/tax | -$91M | -$5M |
| Net IncomeAfter-tax profit | -$80M | -$4M |
| Free Cash FlowCash after capex | -$79M | -$3M |
| Gross MarginGross profit ÷ Revenue | — | +100.0% |
| Operating MarginEBIT ÷ Revenue | — | -2.4% |
| Net MarginNet income ÷ Revenue | — | -170.1% |
| FCF MarginFCF ÷ Revenue | — | -159.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -43.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -16.7% | -2.2% |
MBX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — MBX and CYCN each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | MBXMBX Biosciences, … | CYCNCyclerion Therape… |
|---|---|---|
| Market CapShares × price | $1.6B | $14M |
| Enterprise ValueMkt cap + debt − cash | $1.5B | $10M |
| Trailing P/EPrice ÷ TTM EPS | -18.76x | -2.89x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 6.58x |
| Price / BookPrice ÷ Book value/share | 4.50x | 1.12x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — MBX and CYCN each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
MBX leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
MBX delivers a -20.8% return on equity — every $100 of shareholder capital generates $-21 in annual profit, vs $-39 for CYCN. On the Piotroski fundamental quality scale (0–9), MBX scores 4/9 vs CYCN's 1/9, reflecting mixed financial health.
| Metric | MBXMBX Biosciences, … | CYCNCyclerion Therape… |
|---|---|---|
| ROE (TTM)Return on equity | -20.8% | -39.2% |
| ROA (TTM)Return on assets | -20.1% | -35.6% |
| ROICReturn on invested capital | -96.9% | -65.1% |
| ROCEReturn on capital employed | -40.4% | -55.5% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 1 |
| Debt / EquityFinancial leverage | 0.00x | — |
| Net DebtTotal debt minus cash | -$49M | -$3M |
| Cash & Equiv.Liquid assets | $49M | $3M |
| Total DebtShort + long-term debt | $171,000 | $0 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
MBX leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
MBX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MBX five years ago would be worth $14,677 today (with dividends reinvested), compared to $571 for CYCN. Over the past 12 months, MBX leads with a +220.5% total return vs CYCN's -8.2%. The 3-year compound annual growth rate (CAGR) favors MBX at 13.6% vs CYCN's -19.0% — a key indicator of consistent wealth creation.
| Metric | MBXMBX Biosciences, … | CYCNCyclerion Therape… |
|---|---|---|
| YTD ReturnYear-to-date | +13.6% | +135.1% |
| 1-Year ReturnPast 12 months | +220.5% | -8.2% |
| 3-Year ReturnCumulative with dividends | +46.8% | -46.8% |
| 5-Year ReturnCumulative with dividends | +46.8% | -94.3% |
| 10-Year ReturnCumulative with dividends | +46.8% | -98.7% |
| CAGR (3Y)Annualised 3-year return | +13.6% | -19.0% |
MBX leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — MBX and CYCN each lead in 1 of 2 comparable metrics.
Risk & Volatility
CYCN is the less volatile stock with a 0.94 beta — it tends to amplify market swings less than MBX's 1.33 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MBX currently trades 77.3% from its 52-week high vs CYCN's 37.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MBXMBX Biosciences, … | CYCNCyclerion Therape… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.33x | 0.94x |
| 52-Week HighHighest price in past year | $44.89 | $8.48 |
| 52-Week LowLowest price in past year | $9.43 | $1.03 |
| % of 52W HighCurrent price vs 52-week peak | +77.3% | +37.1% |
| RSI (14)Momentum oscillator 0–100 | 53.7 | 56.0 |
| Avg Volume (50D)Average daily shares traded | 491K | 5.5M |
Evenly matched — MBX and CYCN each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | MBXMBX Biosciences, … | CYCNCyclerion Therape… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $55.33 | — |
| # AnalystsCovering analysts | 4 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MBX leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallMBX Biosciences, Inc. Commo… (MBX)Leads 3 of 6 categories
Loading custom metrics...
MBX vs CYCN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MBX or CYCN a better buy right now?
Analysts rate MBX Biosciences, Inc.
Common Stock (MBX) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MBX or CYCN?
Over the past 5 years, MBX Biosciences, Inc.
Common Stock (MBX) delivered a total return of +46. 8%, compared to -94. 3% for Cyclerion Therapeutics, Inc. (CYCN). Over 10 years, the gap is even starker: MBX returned +46. 8% versus CYCN's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MBX or CYCN?
By beta (market sensitivity over 5 years), Cyclerion Therapeutics, Inc.
(CYCN) is the lower-risk stock at 0. 94β versus MBX Biosciences, Inc. Common Stock's 1. 33β — meaning MBX is approximately 42% more volatile than CYCN relative to the S&P 500.
04Which is growing faster — MBX or CYCN?
On earnings-per-share growth, the picture is similar: Cyclerion Therapeutics, Inc.
grew EPS 9. 9% year-over-year, compared to -81. 4% for MBX Biosciences, Inc. Common Stock. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MBX or CYCN?
MBX Biosciences, Inc.
Common Stock (MBX) is the more profitable company, earning 0. 0% net margin versus -170. 1% for Cyclerion Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MBX leads at 0. 0% versus -239. 8% for CYCN. At the gross margin level — before operating expenses — CYCN leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MBX or CYCN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MBX or CYCN better for a retirement portfolio?
For long-horizon retirement investors, Cyclerion Therapeutics, Inc.
(CYCN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94)). Both have compounded well over 10 years (CYCN: -98. 7%, MBX: +46. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MBX and CYCN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.